Immuno-Oncology Panel Session
Kineticos recently tapped 3 industry veterans and Oncology experts to participate in a panel to discuss where we are today in terms of the Immuno-Oncology treatment landscape and what the future holds. This third installment of the series discusses how biotechs can stand out amongst the myriad of drug developers seeking investment for their I/O programs.
- Chris Heery – Chief Medical Officer, Bavarian Nordic
- Jeff Kmetz – Former Chief Business Officer, Pulse Biosciences
- Alex Dusek – Vice President of Commercial Strategy, Erytech
Click here for a condensed and edited version of Part 3.